ACP
AMAG

Acuta Capital Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

Acuta Capital Partners’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-26,596
Closed -$1.13M – 70
2014
Q4 		$1.13M Buy
+26,596
New +$961K 0.77% 36

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acuta Capital Partners's AMAG Position: Q1 2015 in Review

Acuta Capital Partners sold out of AMAG Pharmaceuticals (AMAG) in Q1 2015, closing a stake of 26,596 shares — an estimated $1.13M sold.

Acuta Capital Partners first reported a position in AMAG in Q4 2014 and held it in 1 quarter. The position peaked at $1.13M in Q4 2014. 197 funds tracked by Wall St. Rank hold AMAG as of Q1 2015.

  • Acuta Capital Partners reported no remaining AMAG Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 26,596 AMAG Pharmaceuticals shares in Q1 2015, an estimated $1.13M.
  • Acuta Capital Partners first reported a position in AMAG Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Acuta Capital Partners's AMAG Pharmaceuticals position peaked at $1.13M in Q4 2014.
  • 197 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2015.

Based on Acuta Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.